NRX Pharmaceuticals
Market cap $109M 44.3M shares (10-Q, Nov 16, 2026) × $2.45 close Nov 17, 2026
Most recent annual filing: 2026-03-23
- NRX-101 Ph3 start2026NRX-101 Ph3 start, 2026, routine
- SPARC-TMS TMS trial start4Q 2026SPARC-TMS TMS trial start, 4Q 2026, routine
- DARPA contract corporate update4Q 2026DARPA contract corporate update, 4Q 2026, routine
- Corporate financials filingNov 2026Corporate financials filing, Nov 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (11 active programs)
D-cycloserine
lurasidone · D-cycloserine/lurasidone · NRX-101D-cycloserine
NRX-101D-cycloserine/lurasidone fixed dose combination
NRX-101anti-HERV-K envelope protein antibody
GNK-301KETAFREE
preservative-free ketamine · ketamine- Anesthesia
KETAFREE
ketamine · preservative-free ketamine · NRX-100pH neutral ketamine
NRX-200Temelimab
anti-HERV-W envelope protein antibodyTechnology platforms
NMDA platform
NMDA receptor-targeting platform for central nervous system disorders including suicidal depression, chronic pain, and PTSD
Targets: NMDA
NMDA receptor platform
NMDA receptor-targeting drug development platform focused on central nervous system disorders including suicidal depression, chronic pain, and PTSD
Targets: NMDA receptor
Capital (as filed)
- Cash
- $19.8M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$6.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $19.8M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-06-03 424B5 · Priced offering 5.71M shares · at $3.50 · $20.0M gross · 24.2% below the prior close ($4.62, Jun 2, 2026)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (18)
- 2026-11-17 UPDATE: NRx Pharmaceuticals (NRXP) - Q3 Status Check: The ATM Napped, the NDA Slipped 🔒 Paid
- 2026-11-11 UPDATE: NRx Pharmaceuticals (NRXP) - The Envelope Becomes the Moat 🔒 Paid
- 2026-10-31 UPDATE: NRx Pharmaceuticals (NRXP) - The Envelope Passed. The Tape Didn’t Care. 🔒 Paid
- 2026-10-01 UPDATE: NRx Pharmaceuticals (NRXP) - The Contract Number Arrives 🔒 Paid
- 2026-09-16 UPDATE: NRx Pharmaceuticals (NRXP) - Major Becomes Minor, and the Clock Gets a Date 🔒 Paid
- 2026-08-15 UPDATE: NRx Pharmaceuticals (NRXP) - The ATM Never Went Dormant 🔒 Paid
- 2026-08-08 UPDATE: NRx Pharmaceuticals (NRXP) - The Cap, Not the Compound 🔒 Paid
- 2026-07-22 UPDATE: NRx Pharmaceuticals (NRXP) - DARPA Picks Up the Phone 🔒 Paid
- 2026-06-24 UPDATE: NRx Pharmaceuticals (NRXP) - Kadima Sues, Zeta Goes Live 🔒 Paid
- 2026-06-03 UPDATE: NRx Pharmaceuticals (NRXP) - The Print Lands at $3.50 🔒 Paid
- 2026-06-02 UPDATE: NRx Pharmaceuticals (NRXP) - The Underwritten Raise Finally Prints 🔒 Paid
- 2026-05-16 UPDATE: NRx Pharmaceuticals (NRXP) - The ATM Receipts Arrive (And a Swiss Surprise) 🔒 Paid
- 2026-05-08 UPDATE: NRx Pharmaceuticals (NRXP) - The Fertilizer Trial Gets a Green Light 🔒 Paid
- 2026-04-27 UPDATE: NRx Pharmaceuticals (NRXP) - The Hail Mary Becomes a Layup 🔒 Paid
- 2026-03-28 UPDATE: NRX Pharmaceuticals - The 10-K Drops, The ATM Spins, and the Evergreen Grab Passes 🔒 Paid
- 2026-03-21 UPDATE: NRX Pharmaceuticals (NRXP) - The FDA Blinks... 🔒 Paid
- 2026-02-14 UPDATE: NRx Pharmaceuticals (NRXP) — The Proxy Drops (And the Math is Ugly) 🔒 Paid
- 2026-01-13 NRx Pharmaceuticals (NRXP): Scientific Deep Dive for KETAFREE™ 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (18 calls)
Every verdict Biotech Distilled has published on NRX Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-13 Watch NRx Pharmaceuticals (NRXP): Scientific Deep Dive for KETAFREE™ Science is plausible but balance sheet is terrifying; wait for FDA signal on preservative ban before committing capital.
- 2026-02-14 Watch UPDATE: NRx Pharmaceuticals (NRXP) — The Proxy Drops (And the Math is Ugly) Proxy confirms massive dilution is being modeled into executive compensation; corporate finance reality is toxic despite plausible science.
- 2026-03-21 Watch UPDATE: NRX Pharmaceuticals (NRXP) - The FDA Blinks... FDA de-risked the NRX-100 pathway materially but a likely secondary offering ahead of earnings keeps the stock on the sidelines.
- 2026-03-28 Watch UPDATE: NRX Pharmaceuticals - The 10-K Drops, The ATM Spins, and the Evergreen Grab Passes 10-K confirms 100%+ dilution in 2025 and active ATM; dilution gap thesis validated, retail investors are just footing the bill for clinical trials.
- 2026-04-27 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Hail Mary Becomes a Layup Three cleared FDA review disciplines and a Presidential EO have materially de-risked the regulatory thesis; wait for the inevitable capital raise to price before entering.
- 2026-05-08 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Fertilizer Trial Gets a Green Light MIND1 IND clearance validates the NRX-101 fertilizer-effect thesis but is a 2027-2028 catalyst; entry still gated on the inevitable capital raise.
- 2026-05-16 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The ATM Receipts Arrive (And a Swiss Surprise) NRX-100 thesis intact and tracking toward Summer 2026 approval; ATM drip already happened at $2.00-$2.94 rather than a discrete offering, complicating the entry-point setup.
- 2026-06-02 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Underwritten Raise Finally Prints The underwritten secondary has finally materialized; wait for the offering to price and look for entry below the offering price with a defined exit at the Summer GDUFA decision.
- 2026-06-03 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Print Lands at $3.50 Offering priced at $3.50 (24% discount); dilution gap bridged through GDUFA decision; consider entering near the offering price with a defined exit at the Summer GDUFA decision.
- 2026-06-24 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - Kadima Sues, Zeta Goes Live Kadima litigation narrows HOPE footprint but doesn't move the NRX-100 GDUFA binary; post-deal soft patch still forming near the $3.50 print.
- 2026-07-22 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - DARPA Picks Up the Phone DARPA selected SPARC-TMS for negotiation, providing a plausible non-dilutive funder for NRX-101; near-term binary remains the Summer GDUFA decision on NRX-100.
- 2026-08-08 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Cap, Not the Compound FDA cleared the drug on every substantive discipline and flagged only a plastic cap attestation; timeline slipped but thesis intact, funded by the June raise.
- 2026-08-15 Hold UPDATE: NRx Pharmaceuticals (NRXP) - The ATM Never Went Dormant Burn rate re-based to $2.2M/month, ATM ran through the quarter described as dormant, and share count up 36% YTD; dilution gap was refinanced not closed, warranting a downgrade to HOLD.
- 2026-09-16 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - Major Becomes Minor, and the Clock Gets a Date FDA reclassified the vial-cap amendment from Major to Minor and set a hard GDUFA goal date of November 10, converting an open-ended cash drain into a defined eight-week hold with a dated outcome.
- 2026-10-01 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Contract Number Arrives DARPA awarded an $11.2M prime contract for SPARC-TMS, meeting the bar set in May; trade still turns on the November 10 GDUFA date for NRX-100.
- 2026-10-31 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Envelope Passed. The Tape Didn't Care. FDA approved preservative-free ketamine ANDA ahead of the November 10 goal date; regulatory risk is gone but the trade is now a launch-and-dilution bet on a generic with no disclosed pricing or exclusivity.
- 2026-11-11 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - The Envelope Becomes the Moat 17-person sales force launched but shipments start January 2027, the same quarter management's cash runway ends; hold through first shipments pending signed supply contracts.
- 2026-11-17 Speculative buy speculative UPDATE: NRx Pharmaceuticals (NRXP) - Q3 Status Check: The ATM Napped, the NDA Slipped Zero Q3 ATM sales and $19.8M cash matched the model, but the branded NDA slipped at least two quarters on a PHQ-9/MADRS comparability question and a $712K aircraft purchase signals governance concerns.
- Long call · opened Apr 27, 2026 at $3.03 · -19.1% vs XBI +9.2% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The NDA is expected to be finalized in Q3 2026.”
matched to NRX-100 ANDA · regulatory decision
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (48)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseNRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Nov 16, 202610-QQuarterly report→ BD updateThe Q3 10-Q reveals NRX burned $19.9M in nine months, holds $19.8M in cash at September 30, and confirms the DARPA contract is signed and already billing — but the runway math is tighter than the post-June-raise bridge implied, and a $712K aircraft on the balance sheet raises new questions.
- Nov 12, 2026ReleaseNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
- Nov 11, 2026ReleaseNRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage→ BD updateNRx just launched its preservative-free ketamine with a 17-person sales force covering 80% of the U.S. market, targeting first shipments in January 2027 and projecting >50% gross margins — the first concrete commercial data point since the October 30 ANDA approval.
- Nov 5, 2026DEFA14AProxy soliciting material
- Nov 5, 2026DEF 14AProxy statement
- Nov 2, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Oct 30, 2026ReleaseNRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date→ BD updateFDA approved KETAFREE (preservative-free ketamine) ahead of the November 10 GDUFA goal date — the exact binary the series has been circling since January. The approval landed; now the question is whether the stock's sharp pre-announcement drop reflects the market selling the news, ATM supply, or something else entirely.
- Oct 29, 2026ReleaseNRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
- Oct 19, 2026ReleaseNRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
- Oct 16, 20268-KCurrent report: other events
- Oct 15, 2026ReleaseNRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free KetamineBD extracted 1 program update from this document → NRXP pipeline
- Oct 5, 20268-KCurrent report: material agreement · EX-99.1 EXHIBIT 99.1
- Sep 30, 2026ReleaseNRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depres→ BD update
- Sep 16, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- Sep 15, 2026ReleaseNRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine→ BD update
- Sep 14, 2026ReleaseGeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)BD extracted 1 program update from this document → NRXP pipeline
- Sep 14, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Sep 11, 2026ReleaseNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
- Sep 8, 2026ReleaseNRx Pharmaceuticals to Participate in Upcoming Investor Conferences
- Aug 17, 2026ReleaseNRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
- Aug 17, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
- Aug 14, 202610-QQuarterly report
- Aug 7, 2026ReleaseNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
- Aug 7, 2026ReleaseFDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for ApprovalBD extracted 1 program update from this document → NRXP pipeline
- Aug 7, 20268-KCurrent report: Reg FD disclosure
- Jul 22, 20268-KCurrent report: other events
- Jun 25, 2026ReleaseNRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
- Jun 25, 2026ReleaseNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
- Jun 24, 2026ReleaseKadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisitionvia aggregator
- Jun 22, 2026ReleaseNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression
- Jun 5, 2026ReleaseNRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.BD extracted 1 program update from this document → NRXP pipeline
- Jun 4, 2026ReleaseNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
- Jun 4, 20268-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
- Jun 3, 2026ReleaseNRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
- Jun 3, 2026424B5Prospectus supplement (offering)
- Jun 2, 2026ReleaseNRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
- Jun 2, 20268-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
- Jun 2, 2026424B5Prospectus supplement (offering)
- May 28, 2026ReleaseEMOCARE is a smartphone-based passive monitoring tool that generates a continuous, real-time measure of depression from patient voice, facial expression, motion, and screen behavior, and is the first
- May 27, 2026ReleaseDeployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and
- May 22, 202625-NSEDelisting notice
- May 18, 2026ReleaseKey highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026,
- May 15, 202610-QQuarterly report
- May 14, 2026ReleaseWILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it
- May 7, 2026ReleasePreliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching hospita
- Mar 24, 20268-KCurrent report: officer / director change, shareholder vote
- Mar 23, 202610-KAnnual report
1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)
- May 15, 2026SCHEDULE 13G/A13G amendment